Achieved the 4th milestone in the AbbVie drug discovery collaboration and received $10 million. In 2026, the 2nd milestone will be reached, and rights to up to $1.2 billion in additional milestones and tiered royalties remain. The 2026 fiscal year outlook already factors in this impact.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4565","jir_company_name":"Nexera Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-06-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4565-20260630-01.pdf","jir_short_summary":"Achieved the 4th milestone in the AbbVie drug discovery collaboration and received $10 million. In 2026, the 2nd milestone will be reached, and rights to up to $1.2 billion in additional milestones and tiered royalties remain. The 2026 fiscal year outlook already factors in this impact.","jir_summary":"### News Highlights\nNexera Pharma has achieved the 4th milestone in its neural disorder drug discovery collaboration with AbbVie, receiving $10 million. The 2nd milestone is expected in 2026, and the company retains rights to up to $1.2 billion in milestones and royalties upon further option exercises and achievement of development and commercialization goals. The impact is already reflected in the 2026 earnings guidance.\n\n### Outlook\nThe collaboration aims to generate new drugs targeting GPCR using the NxWave\u2122 platform, with multiple pipelines progressing in 2026. Most milestones are recognized in 2026, and revenue realization may continue beyond 2027.","jir_financial_highlights":"Milestone receipt amount: 10 million USD (4th milestone achieved)\nAdditional milestone cap: Up to 1.2 billion USD (Based on target achievement for option exercise, development and commercialization)","jir_category":"","jir_hashtags":"#NexeraPharma, #AbbVie, #drug_discovery_collaboration, #neurodegenerative_disease","jir_key_figures":"10 million USD: milestone receipts\nUp to 1.2 billion USD: milestone cap\n2026: 2nd milestone achieved","jir_meta_title":"Nexera Pharma: 4th milestone in AbbVie collaboration achieved | Up to $1.2B in additional milestone rights","jir_meta_description":"Nexera Pharma achieves the 4th milestone in its AbbVie drug discovery collaboration and receives $10 million. The 2nd milestone is expected in 2026. Holds rights to up to $1.2 billion in additional milestones and royalties, already reflected in 2026 guidance.","jir_og_title":"Nexera Pharma announces milestone achievement in AbbVie collaboration","jir_og_description":"Reports the 4th milestone achievement in the AbbVie collaboration. Receipt amount is $10 million; plans to obtain up to $1.2 billion in milestones and royalties going forward. Impact reflected in 2026 guidance.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16880,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-73253","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n